Skip to main content

Table 3 Adverse events related to the study drug (all cycles)

From: Phase I dose-finding study of cabazitaxel administered weekly in patients with advanced solid tumours

  Planned dose level, mg/m2 All
(N = 31)
  1.5 3 6 8.4 10 12  
  (n = 1) (n = 1) (n = 4) (n = 12) (n = 7) (n = 6)   
Adverse event, n G3 G4 G3 G4 G3 G4 G3 G4 G3 G4 G3 G4 G3 G4
Non-haematological               
  Fatigue 3 2 5
  Diarrhoea 1 1 3 5
  Haematuria 1 1
  Febrile neutropenia 1 1
  Dysuria 1 1
Haematological               
  Neutropenia 1 2 1 2
  Anaemia 1 1
Days to neutrophil nadir, median (range) 17 22
32–32 31–31 17–22 18–18 21–22 17–32
Median neutrophil nadir, x 10 9 /l (range) 2.3 2.2 2.2 3.1 2.3
  (3.4–3.4) (1.8–1.8) (1.4–9.0) (0.9–5.0) (1.2–5.7) (0.2–7.3) (0.2–9.0)
  1. G3 Grade 3, G4 Grade 4.